March 21, 2019, MD Magazine 

The U.S. Food and Drug Administration (FDA) has approved brexanolone injection (Zulresso) as the first therapy indicated for the treatment of postpartum depression (PPD) in adult women. The therapy, which was approved for intravenous (IV) use in women enrolled in the Zulresso REMS Program, will only be available through the program, and administered by a care provider in a certified healthcare facility. Women treated with the drug are administered a continuous 60-hour IV infusion. 

Read more.